

Title: Cardiovascular safety of COVID-19 treatments: A disproportionality analysis of adverse event reports from the WHO VigiBase

Cardiovascular safety of COVID-19 treatments: A disproportionality analysis of adverse event reports from the WHO VigiBase

Hoi Ki Cheng¹, Angel Lai¹, Maxwell Kwok², Bryan P Yan^{1,3*}, Ellen N Poon^{2,4,5*}

¹Department of Medicine and Therapeutics, ²School of Biomedical Sciences, ³Heart and Vascular Institute, ⁴Hong Kong Hub of Paediatric Excellence (HK HOPE), ⁵Centre for Cardiovascular Genomics and Medicine, Lui Che Woo Institute of Innovative Medicine, The Chinese University of Hong Kong (CUHK), HKSAR, China

*Correspondence should be addressed to

Ellen Ngar-Yun Poon

E-mail: ellen.poon@cuhk.edu.hk

Tel: (852) 39435750

Add: School of Biomedical Sciences, The Chinese University of Hong Kong, Hong Kong SAR, China

Bryan Yan

E-mail: bryan.yan@cuhk.edu.hk

Division of Cardiology, Department of Medicine and Therapeutics, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, NT, Hong Kong

Tel: (852) 3505 3942

Table S1. Demographic and case characteristics of cardiovascular adverse events reported for studied drugs in Pre-Omicron vs Omicron periods

	Remdesivir		Baricitinib		Tocilizumab		Total	
No. of Reports, n (%)	Pre-Omicron 1622 (22.4)	Omicron 493 (8.4)	Pre-Omicron 172 (2.4)	Omicron 180 (3.1)	Pre-Omicron 290 (4.0)	Omicron 153 (2.6)	Pre-Omicron 7226	Omicron 5865
Regions, n (%)								
Americas	1334 (82.2)	333 (67.5)	171 (99.4)	173 (96.1)	188 (64.8)	128 (83.7)	4929 (68.2)	4042 (68.9)
European Region	237 (14.6)	84 (17.0)	1 (0.6)	5 (2.8)	56 (19.3)	10 (6.5)	1776 (24.6)	1354 (23.1)
Western Pacific	7 (0.4)	39 (7.9)	0 (0.0)	0 (0.0)	19 (6.6)	1 (0.7)	97 (1.3)	118 (2.0)
South-East Asia	20 (1.2)	0 (0.0)	0 (0.0)	0 (0.0)	8 (2.8)	0 (0.0)	153 (2.1)	25 (0.4)
Eastern Mediterranean	24 (1.5)	21 (4.3)	0 (0.0)	0 (0.0)	18 (6.2)	1 (0.7)	268 (3.7)	162 (2.8)
African	0 (0.0)	16 (3.2)	0 (0.0)	2 (1.1)	1 (0.3)	13 (8.5)	3 (0.0)	164 (2.8)
Age Groups, n (%)								
Under 18 years	39 (2.4)	32 (6.5)	0 (0.0)	6 (3.3)	2 (0.7)	0 (0.0)	165 (2.3)	196 (3.3)
18 - 44 years	195 (12.0)	94 (19.1)	33 (19.2)	29 (16.1)	64 (22.1)	25 (16.3)	1504 (20.8)	1497 (25.5)
45-74 years	1011 (62.3)	285 (57.8)	116 (67.5)	127 (70.6)	193 (66.5)	85 (55.6)	4211 (58.2)	3203 (54.6)
>= 75 years	377 (23.2)	82 (16.6)	23 (13.4)	18 (10.0)	31 (10.7)	43 (28.1)	1346 (18.6)	969 (16.5)
Gender, n (%)								
Male	645 (39.8)	225 (45.6)	62 (36.0)	38 (21.1)	80 (27.6)	40 (26.1)	3108 (43.0)	3383 (57.7)
Female	977 (60.2)	268 (54.4)	110 (64.0)	142 (78.9)	210 (72.4)	113 (73.9)	4118 (57.0)	2482 (42.3)
Report Type, n (%)								
Spontaneous	1551 (95.6)	445 (90.3)	170 (98.8)	178 (98.9)	256 (88.3)	143 (93.5)	6214 (86.0)	5297 (90.3)
Report from study	68 (4.2)	45 (9.1)	2 (1.2)	2 (1.1)	18 (6.2)	2 (1.3)	850 (11.8)	521 (8.9)
Other/ Unknown	3 (0.2)	3 (0.6)	0 (0.0)	0 (0.0)	16 (5.5)	8 (5.2)	162 (2.2)	47 (0.8)

Abbreviations: ICSRs; individual case safety reports, CVAEs: cardiovascular adverse events